Pancreatic Cancer Research

ResearcherSun Yat-sen UniversityNo recent work listed

Yanfen Zheng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0467-7487; OpenAlex author ID A5084679597. Sources: OpenAlex.

Their work

Papers
8
Trials
0
Grants
0
Labs led
0
Collaborators
29
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: 4 papers · 2022: 1 paper · 2023: 2 papers

Papers 8

  1. LncRNA BCAN-AS1 stabilizes c-Myc via N6-methyladenosine-mediated binding with SNIP1 to promote pancreatic cancer. Co-author DOI 10.1038/s41418-023-01225-x↗
  2. CSTF2 mediated mRNA N6-methyladenosine modification drives pancreatic ductal adenocarcinoma m6A subtypes. Co-author DOI 10.1038/s41467-023-41861-y↗
  3. Comparing concurrent chemoradiotherapy, 125I seed implantation combined with chemotherapy, and chemotherapy alone efficacy in treating unresectable locally adv… Co-author DOI 10.1002/pro6.1156↗
  4. LINC00842 inactivates transcription co-regulator PGC-1α to promote pancreatic cancer malignancy through metabolic remodelling. Co-author DOI 10.1038/s41467-021-23904-4↗
  5. N6 -methyladenosine-Mediated Upregulation of WTAPP1 Promotes WTAP Translation and Wnt Signaling to Facilitate Pancreatic Cancer Progression. Co-author DOI 10.1158/0008-5472.can-21-0494↗
  6. Inflammatory cytokine-regulated tRNA-derived fragment tRF-21 suppresses pancreatic ductal adenocarcinoma progression. Co-author DOI 10.1172/jci148130↗
  7. Genome-wide identification and characterization of circular RNA m6A modification in pancreatic cancer. Co-author DOI 10.1186/s13073-021-01002-w↗
  8. Excessive miR-25-3p maturation via N6-methyladenosine stimulated by cigarette smoke promotes pancreatic cancer progression. Co-author DOI 10.1038/s41467-019-09712-x↗

Closest collaborators

The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jian Zheng · 7 shared papers, 2019–2023 · strength 0.75
  2. Jiachun Su · 7 shared papers, 2019–2023 · strength 0.75
  3. Jialiang Zhang · 7 shared papers, 2019–2023 · strength 0.75
  4. Dongxin Lin · 7 shared papers, 2019–2023 · strength 0.75
  5. Xudong Huang · 6 shared papers, 2021–2023 · strength 0.68
  6. Ying Ye · 6 shared papers, 2019–2023 · strength 0.64
  7. Rufu Chen · 6 shared papers, 2019–2023 · strength 0.61
  8. Lingxing Zeng · 5 shared papers, 2021–2023 · strength 0.58
  9. Shaoping Zhang · 5 shared papers, 2021–2023 · strength 0.58
  10. Junge Deng · 5 shared papers, 2021–2023 · strength 0.54
  11. Guandi Wu · 4 shared papers, 2021–2023 · strength 0.44
  12. Zhixiang Zuo · 4 shared papers, 2019–2023 · strength 0.40
  13. Lusheng Wei · 4 shared papers, 2021 · strength 0.40
  14. Ling Pan · 4 shared papers, 2019–2021 · strength 0.36
  15. Quanbo Zhou · 2 shared papers, 2023 · strength 0.28
  16. Xu Che · 3 shared papers, 2019–2021 · strength 0.26
  17. Chen Hsuan Wu · 3 shared papers, 2019–2021 · strength 0.26
  18. Rui Li · 2 shared papers, 2021–2023 · strength 0.24
  19. Hongxin Niu · 1 shared paper, 2022 · strength 0.19
  20. Jinbo Yue · 1 shared paper, 2022 · strength 0.19
  21. Chengfeng Wang · 2 shared papers, 2019–2021 · strength 0.16
  22. Rufu Chen · 1 shared paper, 2023 · strength 0.14
  23. Chengfeng Wang · 1 shared paper, 2021 · strength 0.10
  24. Zhiqiang Fu · 1 shared paper, 2019 · strength 0.07
  25. Shengping Li · 1 shared paper, 2019 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.